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DNA sequence is located on chromosome 20. 
Transcription consists of 7 exons and 6 introns, 
spanning 3.6kb. 
A shorter transcription variance (M68E) has been 
identified, and is transcribed from 3 exons and 2 introns 
spanning 1.9kb as illustrated above. The difference 
occurs at the 5' untranslated region, but the two 
transcripts encode the same isoform. Mice do not have 
a gene orthologue to human TNFRSF6B. 




TNFRSF6B protein is 300-amino acid long, and has a  
molecular weight of 35 kD. Although TNFRSF6B 
belongs to the TNFR superfamily, it lacks the 
transmembrane and cytosolic domains in its sequence, 
and is a secreted protein. It contains 4 TNFR cystein-
rich regions, as illustrated above. 
TNFRSF6B can be easily cleaved between Arg218 and 
Ala219 in biological fluids and solutions. It has thus a 
very short (about 20 min) half-life in serum and in 
vivo. Mutation of arginine residue at position 218 to 
glutamine makes TNFRSF6B resistant to proteolysis, 
and significantly prolongs its half-life. TNFRSF6B can 
bind to the TNF family members FasL, LIGHT and 
TL1A. It does not bind to other known TNF family 
members. Human TNFRSF6B can bind to mouse FasL, 
LIGHT and TL1A. This allows human 
DcR3/TNFRSF6B to function in mouse models both in 
vitro and in vivo. The role of TNFRSF6B in apoptosis 
is obvious. FasL is a well-known molecule involved in 
apoptosis. LIGHT is a ligand for HVEM and LTbetaR, 
in addition to being a ligand for TNFRSF6B. LIGHT 
can induce apoptosis in cells expressing both HVEM 
and LTbetaR, or LTbetaR alone. TL1A, a member of 
the TNF family, can evoke apoptosis via its receptor, 
DR3. Consequently, the interaction of TNFRSF6B with 
FasL, LIGHT, and TL1A blocks apoptosis mediated by 
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A) Domains and Motifs. B) TNFRSF6B X-ray crystography. 
 
Expression 
Normal tissue and cells express low-level TNFRSF6B, 
and healthy individuals have near-background serum 
TNFRSF6B levels. About 60% of malignant tumors of 
various tissue origins overexpress TNFRSF6B, and 
these patients have elevated serum TNFRSF6B levels. 
Serum TNFRSF6B levels of tumor patients are 
positively correlated to the degree of tumor malignancy 
and status of metastasis. It is hypothesized that 
malignant tumor cells secrete TNFRSF6B as a way to 
achieve survival advantage by blocking multiple 
apoptosis pathways. 
Hepatocytes in liver cirrhosis have augmented 
TNFRSF6B expression and patients with liver cirrhosis 
have increased serum TNFRSF6B levels. 
TNFRSF6B expression is low in resting T cells but is 
augmented in activated T cells, which probably 
represents a fine-tuning mechanism to balance the need
for clonal expansion and subsequent massive 
activation-induced T cell death. About 40% of systemic 
lupus erythematosus patients have elevated serum 
TNFRSF6B levels. 
TNFRSF6B expression in rheumatoid arthritis 
fibroblast-like synoviocytes is increased by TNFalpha. 
Localisation 
TNFRSF6B is a secreted protein, and is thus detected 
in body fluids. However, it can also be detected in 
cytoplasm before it is secreted. 
Function 
As TNFRSF6B can block ligands from interacting with 
Fas, HVEM, LTbetaR, and DR3, all of which mediate 
apoptosis, it is thus can effectively inhibit apoptosis in 
many cell types. It is believed that many types of 
malignant tumors gain survival advantage by secreting 
TNFRSF6B which blocks tumor cell apoptosis. 
Syngeneic islets transplanted to diabetes recipients 
survive better in the presence of administered 
exogenous human TNFRSF6B, due to the blockage of 
FasL-, LIGHT- and TL1A-triggered islets apoptosis. 
Transgenic expression of human TNFRSF6B in NOD 
mouse islets reduces diabetes pathogenesis, again, due 
to anti-apoptotic effect of TNFRSF6B. 
The forward signaling from FasL to Fas, and from 
LIGHT to HVEM can provide costimulation signals to 
resting T cells. Blocking of these two signaling 
pathways reduces T cell responses to antigens. As 
LIGHT and FasL, although being ligands, are also 
transmembrane proteins, and are capable of reversely 
transducing costimulating signals into T cells, 
TNFRSF6B can also block such reverse signaling. The 
end result is that TNFRSF6B can reduce several 
costimulation pathways in T cells and inhibit T cell 
immune responses, such as cytokine secretion and 
proliferation in vitro, and cardiac allograft rejection in 
vivo in mouse models. 
When human TNFRSF6B is linked to a transmembrane 
domain and is expressed on the mouse tumor cell 
surface, it can effectively trigger T cell costimulation 
via LIGHT and FasL reverse signaling, and cause 
effective tumor vaccination in mouse models. 
When human TNFRSF6B is transgenically expressed 
in mice, it causes a systemic lupus erythrematosus-like 
syndrome. The expression of TNFRSF6B in bone 
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marrow-derived cells is sufficient to induce this 
phenotype. 
Recombinant human TNFRSF6B ameliorates an 
autoimmune crescentic glomerulonephritis model in 
mice. 
TNFRSF6B can influence dendritic cells which in turn 
drive T cells to differentiate into Th2 cells. 
TNFRSF6B can inhibit actin polymerization of T cells 
upon mitogen stimulation, and repress T-cell 
pseudopodium formation, which is known to be 
important for cell-cell interaction. As a consequenc , 
T-cell aggregation after activation is suppressed by 
either soluble or solid phase TNFRSF6B. 
Human T cells pretreated with soluble or solid-phase 
TNFRSF6B are compromised in migration in vitro and 
in vivo toward CXCL12. Mechanistically, a small 
GTPase Cdc42 fails to be activated after TNFRSF6B 
pretreatment of human T cells, and further downstream, 
p38 mitogen-activated protein kinase activation, actin 
polymerization, and pseudopodium formation are all 
down-regulated in the treated T cells. 
Phagocytic activity toward immune complexes and 
apoptotic bodies as well as the production of free 
radicals and proinflammatory cytokines in response to 
lipopolysaccharide are impaired in TNFRSF6B-treated 
macrophages. 
Mutations 




Oncogenesis: TNFRSF6B is overexpressed in about 
60% of various malignant tumors. Its anti-apoptotic 
effect provides the tumors a survival advantage, and its 
role in reducing T cell costimulation favors tumor 
evasion from the immune surveillance. No TNFRSF6B 
gene amplification in tumors has been identified. 
Diagnosis and prognosis: TNFRSF6B in sera or tumor 
can be used as a parameter for tumor diagnosis and 
prognosis. The degree of tumor malignancy is 
correlated to TNFRSF6B levels. When a TNFRSF6B-
expressing tumor is resected, serum TNFRSF6B levels 
will decrease to near-zero level. The re-arising of 
serum TNFRSF6B in such patients will indicate tumor 
reoccurrence. 
Therapeutics: When TNFRSF6B is anchored on tumor 
cell surface, it can increase the antigenicity of the 
tumor, and such TNFRSF6B-expressing tumors can be 
used as tumor vaccine. 
Systemic lupus erythematosus (SLE) 
Disease 
Pathogenesis: About 50% of SLE patients have 
elevated serum TNFRSF6B levels, and the levels 
augment during SLE flare-up. In animal models, 
human TNFRSF6B overexpression in mouse cells of 
hematopoietic origin leads to a SLE-like syndrome, 
suggesting a pathogenic role of TNFRSF6B in SLE. 
Diagnosis: Serum TNFRSF6B can be used as a 
diagnostic parameter for SLE and SLE disease activity. 
Therapeutics: Due to the pathogenic effect of 
TNFRSF6B on SLE, it is speculated that neutralizing 
TNFRSF6B might have therapeutic effect on a 
subpopulation of SLE patients, who are serum 
TNFSF6B positive. 
Islet primary nonfunction during islet 
transplantation 
Disease 
Therapeutics: Due to the anti-apoptotic effect of 
TNFRSF6B, it can effectively protect islets from 
apoptosis during their isolation, transportation, and 
primary non-function after transplantation. 
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